News and Announcements
The newest addition to Fintech Australia’s board Tim Dean Credi’s CEO
- Published July 11, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
For the newest addition to Fintech Australia’s board, the name of the game is helping WA find its place. Tim Dean, founder and CEO of relationship-based lending app Credi, will join the board of Fintech Australia following CrowdfundUP founder Jack Quigley’s departure.Fintech Australia is the fintech industry’s national body, providing everything from networking to advocacy.
Tim said he’s hoping to help WA fintechs, who according to EY currently make up 9% of the industry nationally, carve out their own niche. “[I’ll] be meeting in August [with the CEO of Fintech Australia] to nut out a whole bunch of initiatives that bring fintech in Western Australia into the fold on a more inclusive basis, but also … to develop some initiatives that give fintech WA its own identity,” he said.
“Having an identity is useful because everyone needs a role to play, and it can be a home for a relationship with Asia, then that suddenly can build as a core strength to its offering.”
About Credi Pty Ltd
If you’ve ever loaned your children money you are officially a branch manager of “The Bank of Mum and Dad”. You are also a part of one of fast growing sectors of the Australian economy. Credi.com was born out of the pressing need to document loans between family members, friends and businesses. It removes the stress, the embarrassment and the risk of legal action, formalising a loan within minutes and without a scrap of costly, time-consuming paperwork.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
